Reach Us +44-1647-403003
Role of the Immune Tolerance-Inducing Molecule Indoleamine 2,3-Dioxygenase in Gynecologic Cancers | OMICS International | Abstract
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Role of the Immune Tolerance-Inducing Molecule Indoleamine 2,3-Dioxygenase in Gynecologic Cancers

Kazuhiko Ino*, Yuko Tanizaki, Aya Kobayashi, Saori Toujima, Yasushi Mabuchi and Sawako Minami
Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama, Japan
Corresponding Author : Kazuhiko Ino, MD, PhD
Professor and Chairman
Department of Obstetrics and Gynecology
Wakayama Medical University
811-1 Kimiidera, Wakayama 641-0012, Japan
Tel: 81-(0)73-441-0631
Fax: 81-(0)73-445-1161
E-mail: [email protected]
Received March 29, 2012; Accepted April 19 2012; Published April 21, 2012
Citation: Ino K, Tanizaki Y, Kobayashi A, Toujima S, Mabuchi Y, et al. (2012) Role of the Immune Tolerance-Inducing Molecule Indoleamine 2,3-Dioxygenase in Gynecologic Cancers. J Cancer Sci Ther S13:001. doi:10.4172/1948-5956.S13-001
Copyright: © 2012 Ino K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google


Immune escape and acquisition of tolerance by tumor cells are essential to cancer growth and progression. Therefore, considerable attention has been paid to overcoming the immune resistance of tumors as a novel strategy for cancer therapy. This review focuses on the tryptophan-catabolizing and immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO), and its functional role in gynecologic cancers, such as endometrial cancer, ovarian cancer, cervical cancer, and vulvar cancer. IDO induces tolerance to the host immune surveillance through suppressing the proliferation of effector T-cells or natural killer cells and their killer functions within the tumor microenvironment. In gynecologic cancers, IDO is highly expressed in more than half of cases, and tumoral IDO expression is correlated with advanced surgical stage and impaired patient survival. In preclinical studies in mice, an IDO inhibitor 1-methyltryptophan suppresses tumor growth and peritoneal dissemination, and increases the efficacy of chemotherapeutic agents. In summary, IDO is a novel prognostic indicator for endometrial, ovarian, cervical, and vulvar cancers. IDO inhibition may be a promising strategy to restore host anti-tumor immunity and to enhance the anti-tumor potential of current chemotherapy, radiotherapy, and immunotherapy for gynecologic cancers.


Share This Page